Regulatory Compliance

Beijing – September 22, 2026 -- ADAMA Ltd. (SZSE 000553) has launched Actagon®, a ready-mix pre-emergent herbicide for wheat growers in India, targeting the herbicide-resistant grass weed Phalaris minor.

ADAMA combines two active ingredients into a single ready-mix formulation

Actagon® blends pyroxasulfone and metribuzin in one liquid formulation applied pre-emergence, eliminating the need for on-farm tank mixing. The dual-mode combination is designed to deliver long-lasting control of Phalaris minor along with other grass and broadleaf weeds while supporting resistance management strategies.

Launch targets Punjab and Haryana, India's top wheat-growing states

The rollout focuses on regions where Phalaris minor pressure is highest and farmers face mounting difficulty controlling the weed. Actagon® is registered in India, with commercial launch expected in September 2026.

Philadelphia – September 22, 2026 -- IntegriChain will send five senior advisors to three Informa Connect industry conferences this fall, addressing government pricing, 340B compliance, and gross-to-net forecasting for biopharma manufacturers navigating tightening reimbursement rules.

Government pricing experts present at Chicago's MDRP Summit in October

At the Medicaid Drug Rebate Program (MDRP) Summit 2026, running October 5-7 at the Fairmont Chicago Millennium Park, Jeff Baab, Partner of Advisory Services at IntegriChain, will present "Updates on Landscape of Government Pricing and Contracting" on October 7 at 9:40 AM. The same day at 10:50 AM, Clay Willis, also Partner of Advisory Services, will deliver "340B Movement to Have All 340B Claims in One System of Record," covering the rebate model pilot program #2 and updated patient-definition and contract-pharmacy policies.

New York – September 22, 2026 -- Pomelo Care presented new claims-based data at three major 2026 medical conferences showing its virtual maternity care model cut NICU-related costs per delivery by 63% and reduced average total episode costs by $9,038.

Prenatal engagement with Pomelo cuts NICU stays by 45%, ACOG data shows

At the American College of Obstetricians and Gynecologists annual meeting, Pomelo compared patients who enrolled prenatally against those who joined only after delivery. The prenatal cohort saw a 45% shorter NICU length of stay and a 63% reduction in NICU-related costs per delivery, alongside the $9,038 drop in average total episode cost.

Centreville, Va. – September 22, 2026 -- Just 17% of security leaders are extremely confident in their ability to detect identity-based threats, even though 82% now consider identity the new security perimeter, according to research from CIO Dive's Studio conducted in partnership with ID Dataweb. The same research found 43% of leaders cite fragmented identity systems as their top obstacle to defense.

ID Dataweb, an identity threat detection and risk mitigation provider, released a new buyer's guide, "Identity Threat Detection & Risk Mitigation," aimed at executive and senior security leaders navigating a fragmented vendor landscape. The guide argues that feature checklists and point-product comparisons no longer capture whether a security platform can function as a cohesive, end-to-end system.

Austin, Texas – September 22, 2026 -- Oracle has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment, according to a report published by IDC in August 2026 (Doc #US54122226).

IDC cites Oracle's four-decade track record in real-world data and evidence solutions

The MarketScape credits Oracle with delivering RWD/RWE solutions for over 40 years and aggregating real-world electronic health record data for nearly two decades through its health system network. Oracle expanded its RWD platform following its 2022 acquisition of Cerner and launched a next-generation AI-powered life sciences platform in 2026. The report states Oracle works with every major pharmaceutical company.

Minneapolis – September 22, 2026 -- Claros Technologies has completed a two-week commercial-scale pilot of its ClarosTechUVTM system at Bachem AG's flagship manufacturing campus in Bubendorf, Switzerland, meeting or exceeding the pharmaceutical company's performance metrics for destroying trifluoroacetic acid (TFA) in industrial wastewater.

The trial marks Claros' entry into pharmaceutical manufacturing and expands its commercial footprint in Europe. Bachem, a listed producer of peptide and oligonucleotide APIs including semaglutide, the active ingredient in GLP-1 therapies for weight management and type 2 diabetes, ran the pilot under real-world production conditions.

Debrecen -- CATL began trial production on September 22, 2026 at its newly built battery cell factory in Debrecen, Hungary, after clearing all preconditions tied to its IPPC environmental permit.

Trial run targets first two production lines at Debrecen facility

The trial phase covers the first two production lines of the cell manufacturing plant, following the occupancy permit obtained in August 2026. CATL will use the period to set up, optimize and validate production equipment and manufacturing processes ahead of full series production.

County government confirms earlier compliance deficiencies resolved

The Hajdú-Bihar County Government Office conducted repeated on-site inspections before issuing the occupancy permit, responding to concerns previously raised by local residents. Authority representatives confirmed that CATL had resolved all deficiencies identified earlier in the permitting process.

Fort Lauderdale, Fla. – September 22, 2026 -- CentralReach has launched ReportDraftAI, an AI-assisted tool that compiles authorization, clinical and progress data into a review-ready report draft for Board Certified Behavior Analysts (BCBAs), cutting a process that typically takes 9-12 hours per learner into a fraction of that non-billable time.

BCBAs spend 46% of their time on non-billable documentation, nearly double clinical guidelines

A 2025 study in Behavior Analysis in Practice found behavior analysts devote approximately 46% of their time to indirect activities such as reporting, data analysis and treatment plan development, against a recommended 25-30%. The same documentation load correlates with burnout: 72% of ABA practitioners report medium-to-high burnout tied to reporting demands.

San Diego – September 22, 2026 -- Circular Genomics and Altoida have entered a collaboration pairing blood-based circular RNA (circRNA) biomarkers with AI-powered digital cognitive testing to accelerate Alzheimer's drug development and build a scalable frontline diagnostic pathway.

Companies design a two-step diagnostic workflow combining digital and molecular data

The alliance links Circular Genomics' CircPathTM circRNA biomarker platform with Altoida's Digital NeuroMarkerTM platform. The proposed workflow starts with a 10-minute, self-administered digital cognitive assessment, followed by a confirmatory circRNA blood test to validate underlying disease biology. The companies say this sequence could reduce dependence on hours-long, specialist-administered neuropsychological batteries and extend Alzheimer's screening into primary care settings.

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

SystImmune replaces animal testing with human organ-on-chip models

The IND package for SI-B037 relied on human organ-on-chip systems and primary human tissue models instead of conventional animal studies to assess nonclinical safety. Dr. Jahan Khalili, Senior Vice President of Research at SystImmune, said the human-relevant models provided a more direct read on a molecule engineered to engage multiple human pathways simultaneously.